Investor Presentaiton
2023 Full Year Revenue of RMB 5.39 Billion with 67.8% YoY
Revenue (in Billion RMB)
1.68
91.1%
3.21
67.8%
5.39
Product Sales (in Billion RMB)
2023 Revenue Breakdown (in Million RMB)
2023 2022 2023 revenue for illustration % 2023 share %
1.49
79.0%
2.68
70.2%
4.55
50.7%
2737
1731
2021
2022
2023
2021
2022
2023
9.6%
554
519
20.8%
1120
15.6%
1.1%
Revenue Growth
HANLIKANG
(Rituximab, CD20)
HANDAYUAN
•
Revenue of RMB 5.39B in 2023, 67.8% YoY growth
•
Revenue growth mainly driven by: outperformed sales
ramp-up of HANQUYOU and HANSIZHUANG
•
Gross profit of RMB 3.92B in 2023, 65.3% YoY growth
Product Sales
•
•
Product sales of RMB 4.55B in 2023, 70.2% YoY
growth
•
*Sum of sales revenue of HANQUYOU in China and overseas, and drug substance of trastuzumab
Product sales growth mainly from: HANQUYOU sales
volume open-up with additional capacity released after
Songjiang 1st Plant being approved; HANSIZHUANG
ES-SCLC 1L treatment was approved
•
HANQUYOU
(Trastuzumab, HER2)
(Adalimumab, TNF-α)
Revenue Breakdown
2.2%
841
59 51
339
539
119 0
HANSIZHUANG
(Serplulimab, PD-1)
(Bevacizumab, VEGF)
HANBEITAI
BD &
other income
•
•
HANLIKANG: RMB 519M sales in 2023, -6.4% YoY
HANQUYOU: RMB 2.74B sales* in 2023, 58.1% YoY growth
HANSIZHUANG: RMB 1.12B sales in 2023, 230.2% YoY growth
•
HANDAYUAN: RMB 59M sales in 2023, 14.5% YoY growth
HANBEITAI: RMB 119M sales in 2023
2024 Henlius.
BD and other income: RMB 841M in 2023, 56.0% YoY growth
2 Henlius
38View entire presentation